clonidine has been researched along with Adrenal Cancer in 76 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to evaluate the role of the clonidine suppression test (CST) in the era of analyses of plasma-free metanephrines for the diagnosis or exclusion of PPGL in patients with adrenal tumours and/or arterial hypertension." | 9.51 | Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use. ( Dralle, H; Führer, D; Geroula, A; Pamporaki, C; Schmid, KW; Tsiomidou, S; Unger, N; Van Baal, L; Weber, F, 2022) |
| "The diagnosis of pheochromocytoma/paraganglioma (PPGL) involves detection of elevated levels of plasma and/or 24-h urine catecholamines and/or their metabolites, including metanephrines." | 7.81 | Urinary clonidine suppression testing for the diagnosis of pheochromocytoma. ( Fountoulakis, S; Gordon, RD; Goupil, R; Stowasser, M, 2015) |
| "The clonidine test was used in 80 patients with suspicion of pheochromocytoma (on account of suggestive clinical findings, increased levels of metanephrines, increased plasma or urinary levels of catecholamines, or suggestive images by ultrasonography or CT)." | 7.71 | [Usefulness of the clonidine test for the diagnosis of pheochromocytoma]. ( Fernández-Torres, C; Hidalgo Tenorio, C; Jiménez-Alonso, J; León-Ruiz, L; López de la Torre Casares, M; Mediavilla García, JD; Piédrola Maroto, G; Pinel Julián, P, 2001) |
| " They investigated therefore in 15 patients with essential hypertension (EH) and in three patients with pheochromocytoma the urinary excretion of free noradrenaline (NA), adrenaline (A) and dopamine (DA), the plasma renin activity (PRA), the aldosterone concentration (PAC) and atrial natriuretic factor (ANF) in plasma, using radioimmunoanalysis, always before and 24 hours after clonidine administration (Haemiton retardR) by the oral route." | 7.68 | [The effect of clonidine on humoral factors in patients with arterial hypertension]. ( Dvoráková, J; Gregorová, I; Horký, K; Kopecká, J; Poliak, M, 1990) |
| "We assessed the sensitivity and specificity of glucagon stimulation and clonidine suppression tests in the diagnosis of pheochromocytoma in 113 hypertensive patients, 39 with and 74 without the tumor." | 7.68 | Glucagon and clonidine testing in the diagnosis of pheochromocytoma. ( Goldstein, DS; Grossman, E; Hoffman, A; Keiser, HR, 1991) |
| "Recent investigations have shown that the widely used clonidine suppression test is sometimes fallible for the diagnosis of pheochromocytoma." | 7.68 | Evaluation of clonidine suppression and various provocation tests in the diagnosis of pheochromocytoma. ( Ikeda, M; Koshida, H; Matsubara, T; Miyamori, I; Okamoto, S; Soma, R; Takeda, R, 1990) |
| "Authors assessed correlation between venous blood catecholamines and prostaglandins concentrations before and after inhibition of sympathetic activity by clonidine in patients with primary hypertension or pheochromocytoma." | 7.68 | [Correlations between catecholamines and prostaglandins in patients with primary arterial hypertension and pheochromocytoma in basic conditions and after administration of clonidine]. ( Bar-Andziak, E; Chojnowski, K; Feltynowski, T; Ignatowska-Switalska, H; Lazecki, D; Wocial, B, 1990) |
| "The role of the clonidine suppression test and determination of the plasma concentration of noradrenaline and of neuropeptide Y (NPY) for the diagnosis and monitoring of bilateral pheochromocytoma was studied in a ten year old girl." | 7.68 | [Bilateral adrenal pheochromocytoma. Diagnosis and follow-up using the clonidine test and measurement of plasma neuropeptide Y concentration]. ( Eisenhut, S; Lang, RE; Rascher, W, 1990) |
| "Although it is rarely necessary for the diagnosis of pheochromocytoma, the clonidine suppression test is an accurate and safe test in a select group of patients." | 7.68 | The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. ( Kidd, GS; Simcic, KJ; Sjoberg, RJ, 1992) |
| "To investigate the possible release of beta-endorphins (beta EN) from tumors and to investigate their possible involvement in the hypotensive mechanism of clonidine (CLO) in pheochromocytoma (PHEO), as compared with essential hypertension (EH), we studied 12 patients with PHEO, 17 patients with uncomplicated stable EH (SEH), nine patients with borderline EH (BEH), and seven healthy volunteers (N)." | 7.67 | Plasma beta-endorphins and catecholamines before and after clonidine in essential hypertension and pheochromocytoma. ( Chodakowska, J; Chojnowski, K; Feltynowski, T; Januszewicz, W; Lazecki, D; Wocial, B, 1987) |
| "In the present paper we report our experience on the utility of basal plasma catecholamine (CA) measurement and of the clonidine-suppression test in the diagnosis of pheochromocytoma." | 7.67 | Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. ( Baldi, E; De Feo, ML; Maggi, M; Mannelli, M; Opocher, G; Pupilli, C; Serio, M; Valenza, T, 1987) |
| "In this study we examined the preoperative value of the clonidine-suppression test in 15 patients with surgically proved pheochromocytomas." | 7.67 | Evaluation of the clonidine-suppression test in the diagnosis of pheochromocytoma. ( Beyer, J; Cordes, U; Krause, U; Plewe, G, 1988) |
| "A clonidine suppression test and the measurement of the catecholamine (noradrenaline and adrenaline) concentration in 24-hour urine were undertaken on 13 patients with benign phaeochromocytoma (PCC), 30 patients with benign hypertension (BHT) and ten healthy, normotensive volunteers." | 7.67 | [Diagnostic significance of the clonidine suppression test in suspected pheochromocytoma]. ( Ivens, K; Schürmeyer, T; Stimpel, M; Volkmann, HP; von zur Mühlen, A; Wambach, G, 1988) |
| "In a prospective study designed to differentiate pheochromocytoma from other forms of hypertension, urinary catecholamines were measured after sleep and clonidine administration in 12 patients with pheochromocytoma, 19 hypertensive patients in whom pheochromocytoma was suspected but later excluded, and 31 hypertensive patients in whom pheochromocytoma was never suspected." | 7.67 | Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma. ( Ball, SG; Finlayson, J; Inglis, GC; Isles, CG; Lees, KR; Macdougall, IC; McMillan, NC; Morley, P; Stewart, H; Thomson, I, 1988) |
| " The clonidine suppression of urinary metanephrines as a criterion for the diagnosis of pheochromocytoma is described." | 7.67 | The clonidine test for the diagnosis of pheochromocytoma: the usefulness of urinary metanephrine measurements. ( Andriollo, A; Carvalho, JG; Guerra, EM; Kohlmann, O; Mulinari, RA; Ribeiro, AB; Saad, CI; Zanella, MT, 1987) |
| "Baseline plasma norepinephrine (NE) and epinephrine (E) levels over 2000 pg/ml or failure to suppress to less than 500 pg/ml after oral clonidine have been considered diagnostic of the presence of a pheochromocytoma." | 7.67 | Clonidine suppression test for pheochromocytoma: examples of misleading results. ( Anton, AH; Mayes, D; Taylor, HC, 1986) |
| "23 patients presenting with symptoms of pheochromocytoma were subjected to the clonidine suppression test." | 7.67 | Preliminary results with the clonidine suppression test in the diagnosis of pheochromocytoma. ( Beyer, J; Brandstetter, K; Krause, U, 1985) |
| "1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion." | 7.66 | Intravenous labetalol in the treatment of severe hypertension. ( Brown, JJ; Cumming, AM; Lever, AF; Robertson, JI, 1982) |
| " Clonidine testing resulted in suppression of plasma norepinephrine levels but was complicated by severe hypotension and a transient ischemic attack." | 7.66 | Symptomatic hypotension following the clonidine suppression test for pheochromocytoma. ( Dzau, VJ; Given, BD; Lilly, LS; Taylor, T, 1983) |
| " We aimed to evaluate the role of the clonidine suppression test (CST) in the era of analyses of plasma-free metanephrines for the diagnosis or exclusion of PPGL in patients with adrenal tumours and/or arterial hypertension." | 5.51 | Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use. ( Dralle, H; Führer, D; Geroula, A; Pamporaki, C; Schmid, KW; Tsiomidou, S; Unger, N; Van Baal, L; Weber, F, 2022) |
| "The purpose of this paper is to report our experience and to review the published data on the diagnostic significance and risks of the clonidine suppression test in the diagnosis of pheochromocytoma." | 4.80 | Clonidine suppression test revisited. ( Geiger, H; Lenz, T; Ross, A; Schulte, KL; Schumm-Draeger, P, 1998) |
| "Moderately elevated plasma normetanephrine (NMN) levels are frequent among patients with suspected pheochromocytoma and paraganglioma (PPGL)." | 4.12 | Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. ( Deutschbein, T; Eisenhofer, G; Fassnacht, M; Fuss, CT; Masjkur, J; Nölting, S; Pamporaki, C; Prejbisz, A; Quinkler, M; Remde, H; Timmers, HJLM, 2022) |
| "Borderline isolated norepinephrine (NE) and normetanephrine (NMT) elevation is common among patients with suspected pheochromocytoma and paraganglioma (PPGL)." | 3.96 | The association between systolic blood pressure reduction during clonidine suppression testing and the decrease in plasma catecholamines and metanephrines. ( Fishman, B; Golani, T; Grossman, E; Leibowitz, A; Olswang-Kutz, Y; Sharabi, Y; Shlomai, G, 2020) |
| "The diagnosis of pheochromocytoma/paraganglioma (PPGL) involves detection of elevated levels of plasma and/or 24-h urine catecholamines and/or their metabolites, including metanephrines." | 3.81 | Urinary clonidine suppression testing for the diagnosis of pheochromocytoma. ( Fountoulakis, S; Gordon, RD; Goupil, R; Stowasser, M, 2015) |
| "The aim of this study is to review the experience of the clonidine suppression test in a regional endocrine centre and to compare the diagnostic sensitivity and specificity using various previous published criteria." | 3.77 | Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma. ( Atkinson, AB; Hunter, SJ; McCormick, MT; McHenry, CM; Russell, CF; Smye, MG, 2011) |
| "Measurements of plasma normetanephrine and metanephrine provide a highly sensitive test for diagnosis of pheochromocytoma, but false-positive results remain a problem." | 3.72 | Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. ( Eisenhofer, G; Friberg, P; Goldstein, DS; Keiser, HR; Lenders, JW; Pacak, K; Walther, MM, 2003) |
| "The clonidine test was used in 80 patients with suspicion of pheochromocytoma (on account of suggestive clinical findings, increased levels of metanephrines, increased plasma or urinary levels of catecholamines, or suggestive images by ultrasonography or CT)." | 3.71 | [Usefulness of the clonidine test for the diagnosis of pheochromocytoma]. ( Fernández-Torres, C; Hidalgo Tenorio, C; Jiménez-Alonso, J; León-Ruiz, L; López de la Torre Casares, M; Mediavilla García, JD; Piédrola Maroto, G; Pinel Julián, P, 2001) |
| "Recent investigations have shown that the widely used clonidine suppression test is sometimes fallible for the diagnosis of pheochromocytoma." | 3.68 | Evaluation of clonidine suppression and various provocation tests in the diagnosis of pheochromocytoma. ( Ikeda, M; Koshida, H; Matsubara, T; Miyamori, I; Okamoto, S; Soma, R; Takeda, R, 1990) |
| "Authors assessed correlation between venous blood catecholamines and prostaglandins concentrations before and after inhibition of sympathetic activity by clonidine in patients with primary hypertension or pheochromocytoma." | 3.68 | [Correlations between catecholamines and prostaglandins in patients with primary arterial hypertension and pheochromocytoma in basic conditions and after administration of clonidine]. ( Bar-Andziak, E; Chojnowski, K; Feltynowski, T; Ignatowska-Switalska, H; Lazecki, D; Wocial, B, 1990) |
| " They investigated therefore in 15 patients with essential hypertension (EH) and in three patients with pheochromocytoma the urinary excretion of free noradrenaline (NA), adrenaline (A) and dopamine (DA), the plasma renin activity (PRA), the aldosterone concentration (PAC) and atrial natriuretic factor (ANF) in plasma, using radioimmunoanalysis, always before and 24 hours after clonidine administration (Haemiton retardR) by the oral route." | 3.68 | [The effect of clonidine on humoral factors in patients with arterial hypertension]. ( Dvoráková, J; Gregorová, I; Horký, K; Kopecká, J; Poliak, M, 1990) |
| "We assessed the sensitivity and specificity of glucagon stimulation and clonidine suppression tests in the diagnosis of pheochromocytoma in 113 hypertensive patients, 39 with and 74 without the tumor." | 3.68 | Glucagon and clonidine testing in the diagnosis of pheochromocytoma. ( Goldstein, DS; Grossman, E; Hoffman, A; Keiser, HR, 1991) |
| "The role of the clonidine suppression test and determination of the plasma concentration of noradrenaline and of neuropeptide Y (NPY) for the diagnosis and monitoring of bilateral pheochromocytoma was studied in a ten year old girl." | 3.68 | [Bilateral adrenal pheochromocytoma. Diagnosis and follow-up using the clonidine test and measurement of plasma neuropeptide Y concentration]. ( Eisenhut, S; Lang, RE; Rascher, W, 1990) |
| "Although it is rarely necessary for the diagnosis of pheochromocytoma, the clonidine suppression test is an accurate and safe test in a select group of patients." | 3.68 | The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. ( Kidd, GS; Simcic, KJ; Sjoberg, RJ, 1992) |
| "In the present paper we report our experience on the utility of basal plasma catecholamine (CA) measurement and of the clonidine-suppression test in the diagnosis of pheochromocytoma." | 3.67 | Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma. ( Baldi, E; De Feo, ML; Maggi, M; Mannelli, M; Opocher, G; Pupilli, C; Serio, M; Valenza, T, 1987) |
| "In this study we examined the preoperative value of the clonidine-suppression test in 15 patients with surgically proved pheochromocytomas." | 3.67 | Evaluation of the clonidine-suppression test in the diagnosis of pheochromocytoma. ( Beyer, J; Cordes, U; Krause, U; Plewe, G, 1988) |
| "A clonidine suppression test and the measurement of the catecholamine (noradrenaline and adrenaline) concentration in 24-hour urine were undertaken on 13 patients with benign phaeochromocytoma (PCC), 30 patients with benign hypertension (BHT) and ten healthy, normotensive volunteers." | 3.67 | [Diagnostic significance of the clonidine suppression test in suspected pheochromocytoma]. ( Ivens, K; Schürmeyer, T; Stimpel, M; Volkmann, HP; von zur Mühlen, A; Wambach, G, 1988) |
| "Although originally devised to discriminate between patients with pheochromocytoma and those with elevated plasma catecholamine levels for other reasons, the clonidine suppression test has recently been used in patients with normal resting catecholamine levels." | 3.67 | Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels. ( Elliott, WJ; Murphy, MB, 1988) |
| "In a prospective study designed to differentiate pheochromocytoma from other forms of hypertension, urinary catecholamines were measured after sleep and clonidine administration in 12 patients with pheochromocytoma, 19 hypertensive patients in whom pheochromocytoma was suspected but later excluded, and 31 hypertensive patients in whom pheochromocytoma was never suspected." | 3.67 | Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma. ( Ball, SG; Finlayson, J; Inglis, GC; Isles, CG; Lees, KR; Macdougall, IC; McMillan, NC; Morley, P; Stewart, H; Thomson, I, 1988) |
| " The clonidine suppression of urinary metanephrines as a criterion for the diagnosis of pheochromocytoma is described." | 3.67 | The clonidine test for the diagnosis of pheochromocytoma: the usefulness of urinary metanephrine measurements. ( Andriollo, A; Carvalho, JG; Guerra, EM; Kohlmann, O; Mulinari, RA; Ribeiro, AB; Saad, CI; Zanella, MT, 1987) |
| "Baseline plasma norepinephrine (NE) and epinephrine (E) levels over 2000 pg/ml or failure to suppress to less than 500 pg/ml after oral clonidine have been considered diagnostic of the presence of a pheochromocytoma." | 3.67 | Clonidine suppression test for pheochromocytoma: examples of misleading results. ( Anton, AH; Mayes, D; Taylor, HC, 1986) |
| "To investigate the possible release of beta-endorphins (beta EN) from tumors and to investigate their possible involvement in the hypotensive mechanism of clonidine (CLO) in pheochromocytoma (PHEO), as compared with essential hypertension (EH), we studied 12 patients with PHEO, 17 patients with uncomplicated stable EH (SEH), nine patients with borderline EH (BEH), and seven healthy volunteers (N)." | 3.67 | Plasma beta-endorphins and catecholamines before and after clonidine in essential hypertension and pheochromocytoma. ( Chodakowska, J; Chojnowski, K; Feltynowski, T; Januszewicz, W; Lazecki, D; Wocial, B, 1987) |
| "23 patients presenting with symptoms of pheochromocytoma were subjected to the clonidine suppression test." | 3.67 | Preliminary results with the clonidine suppression test in the diagnosis of pheochromocytoma. ( Beyer, J; Brandstetter, K; Krause, U, 1985) |
| "Fifteen patients with essential hypertension and ten with pheochromocytoma were studied to assess the effect of clonidine, a centrally acting antihypertensive agent, on the functional and biochemical indices of sympathetic function." | 3.66 | Effects of clonidine on sympathetic function. ( Bravo, EL, 1983) |
| " Clonidine testing resulted in suppression of plasma norepinephrine levels but was complicated by severe hypotension and a transient ischemic attack." | 3.66 | Symptomatic hypotension following the clonidine suppression test for pheochromocytoma. ( Dzau, VJ; Given, BD; Lilly, LS; Taylor, T, 1983) |
| "1 We have compared, in patients with severe hypertension, the administration of intravenous labetalol by single rapid injection, by repeated bolus injections, and by incremental infusion." | 3.66 | Intravenous labetalol in the treatment of severe hypertension. ( Brown, JJ; Cumming, AM; Lever, AF; Robertson, JI, 1982) |
| "Pheochromocytomas are catecholamine-producing tumors, representing one of the most important causes of secondary hypertension." | 2.40 | [Clinical and endocrine diagnosis of pheochromocytoma]. ( Kopf, D; Lehnert, H; Mundschenk, J; Schulz, C, 1997) |
| "The clonidine test was very useful, particularly for cases where biochemical results were discrepant." | 1.30 | [A comparative study of 9 cases of adrenal pheochromocytoma and 11 cases of extra-adrenal pheochromocytoma]. ( Aliaga Martínez, L; Fernández-Torres, C; Hidalgo Tenorio, C; López de la Torre Casares, M; Mediavilla García, JD; Muros de Fuentes, MA; Peran Mesa, F, 1999) |
| "The clonidine test was found to be safe and should be preferred to the glucagon test which has to be restricted to very selected patients." | 1.30 | Pheochromocytoma in Italy: a multicentric retrospective study. ( Cilotti, A; Conti, A; Ianni, L; Mannelli, M, 1999) |
| "Hypertension due to pheochromocytoma is generally considered to be a straightforward, direct consequence of the elevated concentrations of circulating catecholamines." | 1.27 | Role of the sympathetic nervous system in the maintenance of hypertension in rats harboring pheochromocytoma. ( Hoffman, BB; Maze, M; Prokocimer, PG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (50.00) | 18.7374 |
| 1990's | 23 (30.26) | 18.2507 |
| 2000's | 5 (6.58) | 29.6817 |
| 2010's | 7 (9.21) | 24.3611 |
| 2020's | 3 (3.95) | 2.80 |
| Authors | Studies |
|---|---|
| Tsiomidou, S | 1 |
| Pamporaki, C | 2 |
| Geroula, A | 1 |
| Van Baal, L | 1 |
| Weber, F | 1 |
| Dralle, H | 2 |
| Schmid, KW | 1 |
| Führer, D | 1 |
| Unger, N | 1 |
| Remde, H | 1 |
| Quinkler, M | 1 |
| Nölting, S | 1 |
| Prejbisz, A | 1 |
| Timmers, HJLM | 1 |
| Masjkur, J | 1 |
| Fuss, CT | 1 |
| Fassnacht, M | 1 |
| Eisenhofer, G | 3 |
| Deutschbein, T | 1 |
| Golani, T | 1 |
| Fishman, B | 1 |
| Sharabi, Y | 1 |
| Olswang-Kutz, Y | 1 |
| Leibowitz, A | 1 |
| Grossman, E | 2 |
| Shlomai, G | 1 |
| Wan, W | 1 |
| Nguyen, B | 1 |
| Graybill, S | 1 |
| Kim, J | 1 |
| Garcha, AS | 1 |
| Cohen, DL | 1 |
| Goupil, R | 1 |
| Fountoulakis, S | 1 |
| Gordon, RD | 4 |
| Stowasser, M | 1 |
| Bisschop, PH | 1 |
| Corssmit, EP | 1 |
| Baas, SJ | 1 |
| Serlie, MJ | 1 |
| Endert, E | 1 |
| Wiersinga, WM | 1 |
| Fliers, E | 1 |
| McHenry, CM | 1 |
| Hunter, SJ | 2 |
| McCormick, MT | 1 |
| Russell, CF | 1 |
| Smye, MG | 1 |
| Atkinson, AB | 2 |
| Yeshayahu, Y | 1 |
| Tallett, S | 1 |
| Pacak, K | 2 |
| De Souza, C | 1 |
| Palmert, MR | 1 |
| Lee, GR | 1 |
| Johnston, PC | 1 |
| McKillop, D | 1 |
| Auld, P | 1 |
| Därr, R | 1 |
| Lenders, JW | 2 |
| Stange, K | 1 |
| Kindel, B | 1 |
| Hofbauer, LC | 1 |
| Bornstein, SR | 1 |
| Bravo, EL | 6 |
| Shargorodsky, M | 1 |
| Zimlichman, R | 1 |
| Goldstein, DS | 2 |
| Walther, MM | 1 |
| Friberg, P | 1 |
| Keiser, HR | 3 |
| Levinson, PD | 1 |
| Lance, BK | 1 |
| Kowarski, AA | 1 |
| Hamilton, BP | 1 |
| Martin, DE | 1 |
| Kammerer, WS | 1 |
| Gifford, RW | 2 |
| Itskovitz, HD | 1 |
| Reid, JL | 1 |
| Meredith, PA | 1 |
| Elliott, HL | 1 |
| Given, BD | 1 |
| Taylor, T | 1 |
| Lilly, LS | 1 |
| Dzau, VJ | 1 |
| Dupont, AG | 2 |
| Velkeniers, B | 1 |
| Somers, G | 2 |
| Gerlo, E | 2 |
| Vanhaelst, L | 2 |
| Gáspár, L | 1 |
| Kiss, Z | 1 |
| Iványi, T | 1 |
| Lászlé, FA | 1 |
| Cumming, AM | 1 |
| Brown, JJ | 1 |
| Lever, AF | 1 |
| Robertson, JI | 1 |
| Burris, JF | 1 |
| D'Angelo, LJ | 1 |
| Tarazi, RC | 1 |
| Fouad, FM | 1 |
| Vidt, DG | 1 |
| McClean, DR | 1 |
| Sinclair, LM | 1 |
| Yandle, TG | 1 |
| Nicholls, MG | 1 |
| Nardecchia, A | 1 |
| Turturro, N | 1 |
| Noviello, F | 1 |
| Vernaglione, L | 1 |
| Pirrelli, A | 1 |
| Mannelli, M | 3 |
| Pupilli, C | 2 |
| Lanzillotti, R | 1 |
| Ianni, L | 2 |
| Amorosi, A | 1 |
| Credi, G | 1 |
| Pratesi, C | 1 |
| Rivero Marcotegui, A | 1 |
| Grijalba Uche, A | 1 |
| Palacios Sarrasqueta, M | 1 |
| Garcia Merlo, S | 1 |
| Sasaki, M | 1 |
| Naomi, S | 1 |
| Iwaoka, T | 1 |
| Lehnert, H | 1 |
| Schulz, C | 1 |
| Mundschenk, J | 1 |
| Kopf, D | 1 |
| Lenz, T | 2 |
| Ross, A | 1 |
| Schumm-Draeger, P | 1 |
| Schulte, KL | 2 |
| Geiger, H | 1 |
| Hug, B | 1 |
| Mediavilla García, JD | 2 |
| López de la Torre Casares, M | 2 |
| Hidalgo Tenorio, C | 2 |
| Fernández-Torres, C | 2 |
| Aliaga Martínez, L | 1 |
| Peran Mesa, F | 1 |
| Muros de Fuentes, MA | 1 |
| Cilotti, A | 1 |
| Conti, A | 1 |
| Zakharov, DA | 1 |
| Lebedinskiĭ, KM | 1 |
| León-Ruiz, L | 1 |
| Piédrola Maroto, G | 1 |
| Pinel Julián, P | 1 |
| Jiménez-Alonso, J | 1 |
| Hengstmann, JH | 1 |
| Dengler, HJ | 1 |
| Rahn, KH | 1 |
| Haas, Th | 1 |
| Denkl, P | 1 |
| Thiede, HM | 1 |
| Nussberger, J | 1 |
| Atlas, SA | 1 |
| Distler, A | 1 |
| Becker, G | 1 |
| Jockenhövel, F | 1 |
| Bauer, R | 1 |
| Lederbogen, S | 1 |
| Lange, R | 1 |
| Reinwein, D | 1 |
| Sjoberg, RJ | 1 |
| Simcic, KJ | 1 |
| Kidd, GS | 1 |
| Hoffman, A | 1 |
| Bachmann, AW | 2 |
| Atzeni, V | 1 |
| Maccioni, G | 1 |
| Fiorenza, M | 1 |
| Bernasconi, M | 1 |
| Beni, M | 1 |
| Chojnowski, K | 2 |
| Feltynowski, T | 2 |
| Lazecki, D | 2 |
| Bar-Andziak, E | 1 |
| Ignatowska-Switalska, H | 1 |
| Wocial, B | 2 |
| Koshida, H | 1 |
| Miyamori, I | 1 |
| Soma, R | 1 |
| Matsubara, T | 1 |
| Okamoto, S | 1 |
| Ikeda, M | 1 |
| Takeda, R | 1 |
| Poliak, M | 1 |
| Horký, K | 1 |
| Kopecká, J | 1 |
| Gregorová, I | 1 |
| Dvoráková, J | 1 |
| Eisenhut, S | 1 |
| Rascher, W | 1 |
| Lang, RE | 1 |
| Chodakowska, J | 1 |
| Januszewicz, W | 1 |
| Hawkins, PG | 1 |
| Meldolesi, J | 1 |
| Gatti, G | 1 |
| Ambrosini, A | 1 |
| Pozzan, T | 1 |
| Westhead, EW | 1 |
| De Feo, ML | 1 |
| Maggi, M | 1 |
| Opocher, G | 1 |
| Valenza, T | 1 |
| Baldi, E | 1 |
| Serio, M | 1 |
| Tunny, TJ | 1 |
| Klemm, SA | 1 |
| Plewe, G | 1 |
| Krause, U | 2 |
| Cordes, U | 1 |
| Beyer, J | 2 |
| Schürmeyer, T | 2 |
| Schuppert, F | 1 |
| von zur Mühlen, A | 2 |
| Stimpel, M | 1 |
| Ivens, K | 1 |
| Wambach, G | 1 |
| Volkmann, HP | 1 |
| Elliott, WJ | 1 |
| Murphy, MB | 1 |
| Macdougall, IC | 1 |
| Isles, CG | 1 |
| Stewart, H | 1 |
| Inglis, GC | 1 |
| Finlayson, J | 1 |
| Thomson, I | 1 |
| Lees, KR | 1 |
| McMillan, NC | 1 |
| Morley, P | 1 |
| Ball, SG | 1 |
| Karlberg, BE | 2 |
| Hedman, L | 2 |
| Prokocimer, PG | 1 |
| Maze, M | 1 |
| Hoffman, BB | 1 |
| Feldstein, JS | 1 |
| Mulinari, RA | 1 |
| Zanella, MT | 1 |
| Guerra, EM | 1 |
| Kohlmann, O | 1 |
| Saad, CI | 1 |
| Andriollo, A | 1 |
| Carvalho, JG | 1 |
| Ribeiro, AB | 1 |
| Taylor, HC | 1 |
| Mayes, D | 1 |
| Anton, AH | 1 |
| Lennquist, S | 1 |
| Pollare, T | 1 |
| Cryer, PE | 1 |
| Frewin, DB | 1 |
| Cerasola, G | 1 |
| Marozzi, P | 1 |
| Morici, ML | 1 |
| Cottone, S | 1 |
| D'Ignoto, G | 1 |
| Grasso, L | 1 |
| Bompiani, GD | 1 |
| Vanderniepen, P | 1 |
| in't Veld, P | 1 |
| Gepts, W | 1 |
| Sacre, R | 1 |
| Six, RO | 1 |
| Brandstetter, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma[NCT01967576] | Phase 2 | 14 participants (Actual) | Interventional | 2013-10-19 | Completed | ||
| Diagnosis and Treatment of Pheochromocytoma[NCT00001229] | 240 participants | Observational | 1988-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01967576)
Timeframe: Date treatment consent signed to date off study, approximately 54 months and 29 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Arm 1-Axitinib | 14 |
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT01967576)
Timeframe: time from start of treatment to time of progression or death, up to 5 years and 9 months
| Intervention | months (Median) |
|---|---|
| 1/Arm 1-Axitinib | 7.7 |
Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or no-target) must have reduction in short axis to <10 mm. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT01967576)
Timeframe: Patients were assessed every 12 weeks (+/- week) up to 40.6 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Confirmed Partial Response | Complete Response | Stable Disease | Progressive Disease | |
| 1/Arm 1-Axitinib | 5 | 0 | 5 | 2 |
12 reviews available for clonidine and Adrenal Cancer
| Article | Year |
|---|---|
Catecholamine excess: pseudopheochromocytoma and beyond.
Topics: Adrenal Gland Neoplasms; Adrenergic Agents; Antihypertensive Agents; Autonomic Nervous System Diseas | 2015 |
Pheochromocytoma: an approach to antihypertensive management.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive | 2002 |
The hypertensive surgical patient. Controversies in management.
Topics: Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Adult; Anesthesia; Animals; Antihypertensive A | 1983 |
Current concepts. Pheochromocytoma: diagnosis, localization and management.
Topics: Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Blood Pressure; Catecholamines; Clonidine; Glu | 1984 |
Clonidine and the kidney.
Topics: Adrenal Gland Neoplasms; Aldosterone; Antihypertensive Agents; Catecholamines; Clonidine; Humans; Hy | 1980 |
Labetalol and the management of hypertension.
Topics: Adrenal Gland Neoplasms; Clonidine; Ethanolamines; Humans; Hypertension; Labetalol; Pheochromocytoma | 1981 |
[Laboratory contribution to the diagnosis of pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Biochemical Phenomena; Biochemistry; Biomarkers; Catecholamines; Chromatogr | 1996 |
[Clonidine suppression test].
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Clonidine; Humans; Pheochromocytoma | 1997 |
[Clinical and endocrine diagnosis of pheochromocytoma].
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Catecholamines; Clonidine; Humans; Iodine Radioisoto | 1997 |
Clonidine suppression test revisited.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Clonidine; Creatinine; Epinephrine; Female; Hemodynamics; Huma | 1998 |
[Influence of antihypertensive agents on catecholamine and metabolite excretion and its significance for the diagnosis of pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Adrenergic beta-Antagonists; Antihypertensive Agents; Catecholamines; Cloni | 1975 |
Phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Blood Pressure; Chromaffin Granules; Chromatography, High P | 1985 |
2 trials available for clonidine and Adrenal Cancer
| Article | Year |
|---|---|
Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use.
Topics: Adrenal Gland Neoplasms; Clonidine; Humans; Hypertension; Metanephrine; Normetanephrine; Paraganglio | 2022 |
[The combined use of fentanyl and clofelin in the anesthesiological support of adrenalectomy].
Topics: Adolescent; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Analgesics; Analgesics, Opioid; Ane | 1999 |
62 other studies available for clonidine and Adrenal Cancer
| Article | Year |
|---|---|
Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine.
Topics: Adrenal Gland Neoplasms; Clonidine; Humans; Metanephrine; Normetanephrine; Paraganglioma; Pheochromo | 2022 |
The association between systolic blood pressure reduction during clonidine suppression testing and the decrease in plasma catecholamines and metanephrines.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Catecholamines; Clonidine; Cross-Sectional Studies; Female; | 2020 |
Clonidine suppression testing for pheochromocytoma in neurofibromatosis type 1.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-2 Receptor Agonists; Clonidine; False Positive Reactions; | 2019 |
Urinary clonidine suppression testing for the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Clonidine; Female; Humans; Male; Metanephrine; Middl | 2015 |
Evaluation of Endocrine Tests. C: glucagon and clonidine test in phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Catecholamines; Clonidine; Female; Glucagon; Humans; Male; Mid | 2009 |
Evaluation of the clonidine suppression test in the diagnosis of phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Catecholamines; Clonidine; Diagnostic Tests, Routi | 2011 |
When is a phaeo not a phaeo? Depression in an adolescent leading to a phaeochromocytoma-like biochemical profile.
Topics: Adolescent; Adrenal Gland Neoplasms; Catecholamines; Clonidine; Depression; Humans; Male; Pheochromo | 2011 |
A comparison of plasma-free metanephrines with plasma catecholamines in the investigation of suspected pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Catecholamines; Chromatography, High Pressure Liqu | 2011 |
[Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine].
Topics: Adrenal Gland Neoplasms; Adult; Aged; Biomarkers; Clonidine; Female; Humans; Male; Middle Aged; Norm | 2013 |
Pheochromocytoma: a disease with many faces.
Topics: Adrenal Gland Neoplasms; Catecholamines; Chromatography, High Pressure Liquid; Clonidine; Diagnosis, | 2002 |
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Tricyclic; Bioc | 2003 |
Catecholamine suppression testing in patient with phaechromocytoma and normal plasma catecholamine levels.
Topics: Adrenal Gland Neoplasms; Clonidine; Epinephrine; Humans; Male; Norepinephrine; Pheochromocytoma; Ref | 1983 |
Effects of clonidine on sympathetic function.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Clonidine; Heart Rate; Humans; Hypertension; Norepinephrine | 1983 |
Pheochromocytoma. Current concepts in diagnosis, localization, and management.
Topics: Adrenal Gland Neoplasms; Adult; Blood Pressure; Catecholamines; Child; Clonidine; Female; Humans; Hy | 1983 |
Symptomatic hypotension following the clonidine suppression test for pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; Humans; Hypotension; Male; Pheochromocytoma | 1983 |
Unusual clonidine-suppression test in an epinephrine-secreting pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Animals; Clonidine; Epinephrine; Humans; Male; Pheochromocytoma; Rat | 1984 |
Clonidine-suppression test for diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; Humans; Male; Pentolinium Tartrate; Pheochromocytoma | 1982 |
Clonidine suppression test in pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Clonidine; Epinephrine; Humans; Norepinephrine; Pheochromocytoma | 1982 |
Intravenous labetalol in the treatment of severe hypertension.
Topics: Adrenal Gland Neoplasms; Catecholamines; Clonidine; Ethanolamines; Humans; Hypertension; Infusions, | 1982 |
Complications of clonidine suppression test for pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Clonidine; Female; Humans; Hypertension; Male; Middle Aged; Pheochromocytom | 1982 |
Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Clonidine; Epinephrine; Heart Rate; Humans; Norepinephrine; | 1981 |
Malignant phaeochromocytoma with high circulating DOPA, and clonidine-suppressible noradrenaline.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Agonists; Aged; Clonidine; Dihydroxyphenylalanine; Humans; | 1995 |
Positive responses to clonidine test in nephrovascular hypertension: only a false positive?
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; False Positive Reactions; Female; Humans; Hyperaldosteron | 1994 |
A nonsecreting pheochromocytoma presenting as an incidental adrenal mass. Report on a case.
Topics: Adrenal Gland Neoplasms; Adult; Blood Pressure; Catecholamines; Clonidine; Female; Glucagon; Heart R | 1993 |
[Panic disorder].
Topics: Adrenal Gland Neoplasms; Aged; Clonidine; Diagnosis, Differential; Epinephrine; Female; Humans; Nore | 1998 |
[A comparative study of 9 cases of adrenal pheochromocytoma and 11 cases of extra-adrenal pheochromocytoma].
Topics: 3-Iodobenzylguanidine; Abdominal Neoplasms; Adrenal Gland Neoplasms; Adrenergic alpha-Agonists; Adul | 1999 |
Pheochromocytoma in Italy: a multicentric retrospective study.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Child; Clonidine; Epinephrine; | 1999 |
[Usefulness of the clonidine test for the diagnosis of pheochromocytoma].
Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Clonidine; Female; Humans; Male; Middle Aged; Pheoch | 2001 |
[Therapy of hypertensive crisis].
Topics: Acute Disease; Adrenal Gland Neoplasms; Antihypertensive Agents; Clonidine; Diazoxide; Dihydralazine | 1977 |
[Therapy of hypertensive crises].
Topics: Acute Disease; Adrenal Gland Neoplasms; Antihypertensive Agents; Clonidine; Diazoxide; Dihydralazine | 1977 |
Hyperreninemia and secondary hyperaldosteronism in a patient with pheochromocytoma and von Hippel-Lindau disease.
Topics: Adrenal Gland Neoplasms; Adult; Captopril; Catecholamines; Clonidine; Female; Humans; Hyperaldostero | 1992 |
Cervical pheochromocytoma: a rare localization and a difficult diagnosis.
Topics: Adrenal Gland Neoplasms; Catecholamines; Clonidine; Female; Glucagon; Humans; Middle Aged; Pheochrom | 1992 |
The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls.
Topics: Adrenal Gland Neoplasms; Aged; Clonidine; Evaluation Studies as Topic; Humans; Male; Neoplasms, Mult | 1992 |
Pheochromocytoma: new concepts and future trends.
Topics: Acidosis, Lactic; Adrenal Gland Neoplasms; Adult; Animals; Antihypertensive Agents; Antineoplastic C | 1991 |
Surreptitious self-administration of epinephrine resulting in 'pheochromocytoma'.
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; Epinephrine; Factitious Disorders; Female; Humans; Muncha | 1991 |
Glucagon and clonidine testing in the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Catechols; Clonidine; Drug Therapy, Combination; Glucagon; Humans; Hyperten | 1991 |
Clonidine suppression test reliably differentiates phaeochromocytoma from essential hypertension.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Clonidine; Diagnosis, Differential; Epinephrine; F | 1991 |
[Pheochromocytoma diagnosed during quinapril therapy].
Topics: Adrenal Gland Neoplasms; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clonidin | 1990 |
[Correlations between catecholamines and prostaglandins in patients with primary arterial hypertension and pheochromocytoma in basic conditions and after administration of clonidine].
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; Dinoprost; Dinoprostone; Epinephrine; Humans; Hypertensio | 1990 |
Evaluation of clonidine suppression and various provocation tests in the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Blood Pressure; Clonidine; Epinephrine; Female; Glucagon; Huma | 1990 |
[The effect of clonidine on humoral factors in patients with arterial hypertension].
Topics: Adrenal Gland Neoplasms; Aldosterone; Atrial Natriuretic Factor; Catecholamines; Clonidine; Diagnosi | 1990 |
[Bilateral adrenal pheochromocytoma. Diagnosis and follow-up using the clonidine test and measurement of plasma neuropeptide Y concentration].
Topics: Adrenal Gland Neoplasms; Child; Clonidine; Female; Humans; Neoplasms, Multiple Primary; Neuropeptide | 1990 |
Plasma beta-endorphins and catecholamines before and after clonidine in essential hypertension and pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; beta-Endorphin; Blood Pressure; Catecholamines; Clonidine; Dopamine; | 1987 |
Phaeochromocytomas secreting adrenaline but not noradrenaline do not cause hypertension and require precise adrenaline measurement for diagnosis.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Chromatography, High Pressure Liquid; Clonidine; E | 1989 |
Second-messenger control of catecholamine release from PC12 cells. Role of muscarinic receptors and nerve-growth-factor-induced cell differentiation.
Topics: Adrenal Gland Neoplasms; Animals; Carbachol; Catecholamines; Cell Differentiation; Clonidine; Colfor | 1988 |
Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Catecholamines; Clonidine; Epinephrine; Female; Hu | 1987 |
Effects of angiotensin and noradrenaline on atrial natriuretic peptide levels in man.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Angiotensin II; Atrial Natriuretic Factor; Clonidi | 1987 |
Evaluation of the clonidine-suppression test in the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; Epinephrine; Female; Humans; Male; Middle Aged; Norepinep | 1988 |
[Preoperative diagnosis of suspected pheochromocytoma--retrospective assessment of diagnostic criteria].
Topics: Adrenal Gland Neoplasms; Adult; Aged; Clonidine; Diagnostic Imaging; Dopamine; Epinephrine; Female; | 1988 |
[Diagnostic significance of the clonidine suppression test in suspected pheochromocytoma].
Topics: Adrenal Cortex Function Tests; Adrenal Gland Neoplasms; Adult; Clonidine; Epinephrine; Evaluation St | 1988 |
Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels.
Topics: Adrenal Gland Neoplasms; Clonidine; False Positive Reactions; Humans; Norepinephrine; Pheochromocyto | 1988 |
Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Blood Pressure; Catecholamines; Clonidine; Female; Humans; Mal | 1988 |
Value of the clonidine suppression test in the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Blood Pressure; Catecholamines; Clonidine; Dopamine; Epinephrine; Hu | 1986 |
Role of the sympathetic nervous system in the maintenance of hypertension in rats harboring pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Animals; Chlorisondamine; Clonidine; Hypertension; Naloxone; Pheochromocyto | 1987 |
Hypertensive emergencies.
Topics: Adrenal Gland Neoplasms; Angina Pectoris; Antihypertensive Agents; Aortic Aneurysm; Aortic Dissectio | 1986 |
The clonidine test for the diagnosis of pheochromocytoma: the usefulness of urinary metanephrine measurements.
Topics: Adrenal Gland Neoplasms; Blood Pressure; Clonidine; Epinephrine; Humans; Metanephrine; Pheochromocyt | 1987 |
Clonidine suppression test for pheochromocytoma: examples of misleading results.
Topics: Adrenal Gland Neoplasms; Adrenal Medulla; Catecholamines; Clonidine; Epinephrine; False Negative Rea | 1986 |
The value of the clonidine-suppression test in the diagnosis of pheochromocytoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Blood Pressure; Catecholamines; Clonidine; Female; | 1986 |
Clonidine. Quo vadis?
Topics: Adrenal Gland Neoplasms; Anxiety Disorders; Climacteric; Clonidine; Female; Humans; Hypertension; Mi | 1985 |
[Scintigraphy with 131I-metaiodobenzylguanidine in the differential diagnosis of pheochromocytoma].
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Clonidine; Humans; Hypertension; Iodine Radioisotope | 1985 |
Clonidine-suppression test in epinephrine secreting pheochromocytoma: report of a case.
Topics: Adrenal Gland Neoplasms; Adult; Clonidine; Cytoplasmic Granules; Epinephrine; Humans; Male; Microsco | 1985 |
Preliminary results with the clonidine suppression test in the diagnosis of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Clonidine; Diagnosis, Differential; Epinephrine; Humans; Hypertension; Nore | 1985 |